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A R T I C L E I N F O

A B S T R A C T
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Direct-acting oral anticoagulants (DOACs) represent the standard for preventing stroke and systemic emboli
zation (SSE) in patients with atrial fibrillation (AF). There is limited information for patients ≥ 80 years. We
report a retrospective analysis of AF patients ≥ 80 years prescribed either a US Food and Drug Administration
(FDA)-approved reduced (n = 514) or full dose (n = 199) DOAC (Dabigatran, Rivaroxaban, or Apixaban) be
tween January 1st, 2011 (first DOAC commercially available) and May 31st, 2017. The following multivariable
differences in baseline characteristics were identified: patients prescribed a reduced dose DOAC were older (p <
0.001), had worse renal function (p = 0.001), were more often prescribed aspirin (p = 0.004) or aspirin and
clopidogrel (p < 0.001), and more often had new-onset AF (p = 0.001). SSE and central nervous system (CNS)
bleed rates were low and not different (1.02 vs 0 %/yr and 1.45 vs 0.44 %/yr) for the reduced and full dose
groups, respectively. For non-CNS bleeds, rates were 10.89 vs 4.15 %/yr (p < 0.001, univariable) for the reduced
and full doses, respectively. The mortality rate was 6.24 vs 1.75 %/yr (p = 0.001, univariable) for the reduced
and full doses. Unlike the non-CNS bleed rate, mortality rate differences remained significant when adjusted for
baseline characteristics. Thus, DOACs in patients ≥ 80 with AF effectively reduce SSE with a low risk of CNS
bleeding, independent of DOAC dose. The higher non-CNS bleed rate and not the mortality rate is explained by
the higher risk baseline characteristics in the reduced DOAC dose group. Further investigation of the etiology of
non-CNS bleeds and mortality is warranted.

1. Introduction
Atrial fibrillation (AF) is a modern epidemic with a prevalence of up
to 23.5 % in the rapidly growing elderly population ≥ 80 years [1–3]. AF
is associated with an increased risk of stroke and systemic embolization
(SSE), as well as mortality [4–5]. In addition, strokes related to AF tend
to be more debilitating and severe than strokes not associated with AF

[6–8].
Since 2009, four direct-acting oral anticoagulants (DOACs), dabi
gatran, rivaroxaban, apixaban, and edoxaban, have been compared to
warfarin in prospective randomized clinical trials for stroke prevention
in patients with atrial fibrillation [9–12]. Reduced and full doses of all
DOACs have been approved by the US Food and Drug administration
(FDA) on the basis of these trials to prevent SSE in patients with AF,

Abbreviations: AF, atrial fibrillation; SSE, stroke and systemic embolization; DOACs, direct-acting oral anticoagulants; D150, Dabigatran 150 mg twice daily;
D110, Dabigatran 110 mg twice daily; D75, Dabigatran 75 mg twice daily; R20, Rivaroxaban 20 mg daily; R15, Rivaroxaban 15 mg daily; A5, Apixaban 5 mg twice
daily; A2.5, Apixaban 2.5 mg twice daily; CrCl, creatinine clearance; FDA, Food and Drug Administration; BMMSA, Bryn Mawr Medical Specialists Association; CNS,
central nervous system; CKD, chronic kidney disease; ESRD, end-stage renal disease.
* Corresponding author at: 214 N Ithan Ave, Villanova, PA 19085, USA.
E-mail address: michael.ezekowitz@comcast.net (M.D. Ezekowitz).
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Variable

Reduced dose, total (n =
514)

Full dose, total (n =
199)

Pvalue*

D75,
(n = 53)

D150
(n = 57)

Pvalue*

R15,
(n = 224)

R20,
(n = 74)

P
value*

A2.5,
(n = 236)

A5,
(n = 68)

Age (mean +/- 1SD)

86.8 ± 3.9

83.2 ± 1.4

<0.001

86 ± 3.3

< 0.001

86.8 ± 3.8

82.5 ± 4.2

< 0.001

87.1 ± 4.1

84.5 ± 0.7

Men, n (%)

206 (40.2)

97 (48.7)

30 (56.6)

82.7 ±
1.4
24 (42.1)

83 (37.2)

39 (52.7)

< 0.001

92 (38.8)

25.4 ± 5.13

27.2 ± 1.2

26.2 ± 4.3

27.9 ± 3

25.7 ± 5.4

26.4 ± 3.2

24.9 ± 4.9

34
(50)
27.4 ± 3.3

12 (22.6)
27 (50.9)

4 (7)
29 (50.9)

16 (21.6)
33 (44.6)

91 (38.4)
95 (40.1)

25 (36.8)
25 (36.8)

13 (24.5)

24 (42.1)

49 (20.7)

18 (26.4)

15 (26.3)

86
(36)
5 (2.1)
29 (12.2)
1 (0.5)
42.5 ±
16.4
1.29 ± 0.9
12.1 ± 1.8
7.3 ± 2.93

21 (30.9)

2 (3.5)
1 (1.8)
0
60.8 ±
6.4
1.0 ± 0.2
13 ± 0.6
8.8 ± 1.3

78 (35)
98
(43.9)
44
(19.7)
103
(46)
4 (1.8)
14 (6.3)
1 (0.5)
45.7 ±
15.3
1.13 ± 0.4
12.5 ± 1.6
7.25 ±
2.29
221 ± 74

2

182 (35.4)
220 (42.8)

45 (22.6)
87 (43.7)

Chronic AF, n (%)

107 (20.8)

67 (33.7)

Aspirin use, n (%)

209 (45.34)

52 (26.1)

Clopidogrel use, n (%)
Aspirin + Clopidogrel use, n (%)
Aspirin + Other antiplatelet use, n (%)
Creatinine clearance (mL/min)

10 (2.17)
50 (10.85)
3 (0.6)
44.1 ± 16.0

5 (2.5)
3 (1.5)
1 (0.5)
59.4 ± 14.1

Serum Creatinine
Hemoglobin (g/dL)
WBC count (x 109/L)

1.22+0.67
12.32 ± 1.7
7.48 ± 3.7

0.99+0.21
12.9 ± 1.5
7.8 ± 1.1

Platelet count (x 109/L)

213.94 ± 74

217.2 ± 45.3

20
(38)
1 (1.9)
7 (13 %)
1 (1.9)
45.4 ±
16.8
1.25 ± 0.4
12.8 ± 1.8
8.36 ±
8.40
193 ± 56

Stroke/TIA, n (%)

99 (19.3)

33 (16.6)

12 (22.6)

11 (19.3)

Systemic embolism, n (%)
Myocardial infarction, n (%)
Valvular Heart Disease, n (%)

2 (0.4 %)
73 (14.2)
365 (71)

0
15 (7.5)
124 (62.3)

1 (1.9)
10 (18.9)
39 (73.6)

0
1 (1.8)
35 (61.4)

Valve replacement/repair, n (%)
Heart failure, n (%)
Diabetes Mellitus, n (%)
Hypertension, n (%)
Coronary Artery Disease, n (%)
Peripheral Artery Disease, n (%)
Carotid disease, n (%)
Hypercoagulable State, n (%)
Coronary Stent(s), n(%)

35 (6.8)
163 (31.7)
87 (16.9)
364 (70.8)
169 (36.8)
33 (6.4)
43 (8.4)
3 (0.6)
99 (19.3)

6 (3)
27 (13.6)
32 (16.1)
151 (75.9)
67 (33.7)
9 (4.5)
10 (5)
1 (0.5)
23 (11.6)

6 (11.5)
16 (30.2)
6 (11.3)
37 (69.8)
25 (47.2)
2 (3.8)
1 (1.9)
0
14 (26.4)

CABG, n (%)
Pacemaker, n (%)

46 (8.9)
137 (26.7)

14 (7)
42 (22.1)

6 (11.3)
16 (30.2)

3 (5.3)
8 (14)
10 (17.5)
43 (75.4)
19 (33.3)
3 (5.3)
4 (7)
1 (1.8)
5
(8.8)
5 (8.8)
15 (26.3)

Ablation, n (%)

62
(12.1)
4 (0.8)

21
(10.5)
1 (0.5)

6
(11.3)
0

6
(10.5)
0

37
(16.6)
0
24 (10.8)
156
(70)
19 (8.5)
59 (26.5)
39 (17.5)
162 (72.6)
78 (35)
20 (9)
17 (7.6)
2 (0.9)
35
(15.7)
22 (9.9)
58
(26)
33
(14.8)
3 (1.3 %)

268
(52.1)

167 (83.9)

15
(28.3)

55
(100)

135
(60.3)

<0.001
< 0.001

0.004
< 0.001
< 0.001

< 0.033
0.01

0.037

203 ± 1.4

2
Left atrial appendage (LAA) closure, n
(%)
Prescription as per label, n (%)

<0.001

0.05

< 0.001
< 0.001
0.05

25 (33.8)
16 (21.6)

0.003

3 (4.1)
0
0
59.3 ± 0.7
0.99 ± 0.2
12.9 ± 0.8
7.3 ± 0.5

< 0.001

0
2 (2.9)
1 (1.5)
58.4 ± 16.3

212 ± 77
49 (20.7)

225.1 ±
101.8
14 (20.6)

0
5 (6.8)
48 (64.9)

1 (0.5)
40 (16.9)
168 (70.9)

0
9 (13.2)
41 (60.3)

2 (2.7)
7 (9.5)
8 (10.8)
54 (73)
22 (29.7)
2 (2.7)
1 (1.4)
0
7
(9.5)
7 (9.5)
12 (16.2)

9 (3.9)
89 (37.6)
41 (17.3)
163 (68.8)
85 (35.9)
11 (4.6)
24 (10.1)
1 (0.5)
49 (20.7)

1 (1.5)
12 (17.6)
14 (20.6)
54 (79.4)
26 (38.2)
4 (5.9)
5 (7.4)
0
11 (16.2)

19 (8)
64
(27)
23 (9.7)

2 (3)
15 (22.1)

0.011

7
(9.5)
0
49
(70)

0.03

0.044
< 0.001

0.98 ± 0.2
12.7 ± 0.42
7.4 ± 1.13

221.1 ±
109.6
8 (10.8)

NS
NS

0.004

1 (0.5)

8
(11.8)
1 (1.5)

119
(50.4)

63
(92.6)

0.004

< 0.001

D75 = Dabigatran 75 mg twice daily; D150 = Dabigatran 150 mg twice daily; R15 = Rivaroxaban 15 mg once daily; R20 = Rivaroxaban 20 mg once daily; A2.5 = Apixaban 2.5 mg twice daily; A5 = Apixaban 5 mg twice
daily.
*
All p-values are from multivariable stepwise regression.
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BMI (kg/m )
AF Type
New-onset AF, n (%)
Paroxysmal AF, n (%)

Pvalue*
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Table 1
Baseline Characteristics of patients prescribed reduced and full dose DOAC.
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Fig. 1. Outcomes in all patients prescribed a reduced or full dose DOAC (mean ± 1 SD).
Table 2
Time to event comparison between the combined reduced and full dose DOACs.
Events
(%/yr)
SSE
CNS
bleeding
Non-CNS
bleeding
All-cause
mortality

Reduced dose DOACs
combined group rate per
person-yeara (n = 514)

Full dose DOACs combined
group rate per person-yeara
(n = 199)

p-value univariable (from
log rank test with KaplanMeier curve)

1.02
1.45

0
0.44

0.035
0.109

10.89

4.15

< 0.001

6.24

1.75

< 0.001

Proportional hazards multivariable
hazard ratio: Low dose as reference
(95 % CI)*

p-value from proportional
hazards multivariable
model*

N/A b
0.291
(0.054 to 1.56)
0.72
(0.395 to 1.312)
0.338
(0.142 to 0.807)

N/A b
0.204
0.249
0.013

SSE = Stroke and systemic embolization; CNS = central nervous system.
a
Rates per person-year may be interpreted as annual percentages.
b
Too few cases in one group for multivariable model.
*
p values and hazard ratio adjusted for multivariable baseline differences.

representing a significant medical advancement [13–14]. The reduced
doses of the DOACs were tested in pivotal clinical trials, except for
Dabigatran 75 mg twice daily (D75), which was approved by the FDA
based on pharmacokinetic modeling and simulation [15–17]. Following
the approval of D75, a study of patients with chronic kidney disease
(CKD) confirmed the exposure levels predicted by the dosing simula
tions [18].
In a prior publication, we performed a retrospective analysis of pa
tients ≥ 80 years with atrial fibrillation from the Bryn Mawr Medical
Specialists Association (BMMSA) database who were prescribed either
the reduced dose DOAC or warfarin [19]. The reported rates of SSE
trended lower in the reduced dose DOAC group [19]. The rate of central
nervous system (CNS) bleeds was low in both groups [19]. The rates of
major bleeding and all-cause mortality were higher in the reduced dose
DOAC group compared to warfarin [19].
In this report, we extend the review of the BMMSA database to
include patients > 80 years of age with AF who were prescribed a full
dose DOAC. Thus, a direct comparison in a real-world population of the
reduced dose DOAC with the full dose DOAC was possible.

The clinical outcomes collected were SSE, CNS bleeding, non-CNS
bleeding, and all-cause mortality. All outcomes were reported as the
time-to-first-event. Additional data collected included time to switching
anticoagulants, discontinuation of anticoagulation, and the number of
patients lost to follow-up. The time periods after these events were
excluded from the analysis. Patients who completed the observation
period without any outcome event were identified (Fig. 1).
A stroke was defined as a sudden focal neurological deficit confirmed
with either CT or MRI as a proven embolic event that persisted beyond
24 hours. CNS bleeding was defined as intracranial and/or spinal bleeds
as identified by imaging. A non-CNS bleed was defined as any nonneurological bleeding event that led to DOAC discontinuation for
more than 2 weeks. Mortality data were obtained from the BMMSA and
Main Line Health databases and publicly available death notices. The
cause of death was only available if the death occurred in a hospital
setting or if the office database included notice of hospice status for a
particular cause. Patients lost to follow-up were defined as any patient
who was last seen 3 months or more before the last date of this retro
spective analysis, May 31st, 2017.
The first analysis compared the baseline characteristics of all patients
prescribed either a reduced dose or a full dose DOAC, independent of the
specific DOAC used. The second analysis compared individual reduced
and full dose DOACs. Both analyses began with univariable testing fol
lowed by a multivariable test of those characteristics that showed a
difference in the univariable analysis. The univariable tests included
unpaired t-tests for normally distributed numeric variables, MannWhitney U tests for non-normal numeric variables, and Chi-square or
Fisher Exact tests for non-numeric variables. These analyses were fol
lowed by a stepwise multivariable logistic regression in which all
characteristics that were univariably different at p ≤ 0.10 were entered
into the model, thus ensuring that confounding variables were consid
ered. The stepwise model retained variables that attained p ≤ 0.05.
Outcome events were compared between the reduced and the full

2. Methods
This study is an institutional review board-approved retrospective
analysis of the BMMSA outpatient electronic records and the inpatient
Mainline Health SmartChart database between January 1st, 2011, when
Dabigatran was first commercially available, and May 31st, 2017. Two
teams of investigators collected the data. Team 1 had access to patient
records and collected the data in a de-identified format. Team 2 entered
the data into the Microsoft Excel database without knowledge of patient
identity [19]. We identified 514 patients who were prescribed the FDAapproved reduced dose DOACs and 199 who were prescribed the FDAapproved full dose DOACs. The baseline characteristics of these pa
tients were compared, as shown in Table 1.
3
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< 0.001
0
4.2
0.41
3.8
5.5

dose DOAC groups using Kaplan-Meier curves and log-rank tests. These
analyses were then followed by multivariable proportional hazards
models to adjust for the baseline variables that were significantly
different between reduced and full dose DOACs (p ≤ 0.05) in the step
wise multivariable logistic regression analyses. To obtain person-year
rates, the number of outcome events was divided in each group by the
total years of follow-up for that specific group. P -values were generated
by log-rank tests.
The reduced and full doses of DOAC were defined based on the
published US consensus statement for the management of patients with
atrial fibrillation [13–14].
For apixaban, the full dose is 5 mg twice daily (A5). The dose is
reduced to 2.5 mg twice daily (A2.5) if the patient meets 2 out of the 3
following criteria: age ≥ 80 years, weight ≤ 60 kg, or creatinine ≥ 1.5
mg/dL.
For dabigatran, the full dose is 150 mg twice daily (D150) if creati
nine clearance is > 30 mL/min. The dose is reduced to 75 mg twice daily
(D75) if creatinine clearance is 15–30 mL/min. Of note, D75 outcome
data has not been reported outside the BMMSA database [19].
For rivaroxaban, the full dose is 20 mg daily (R20). The dose is
reduced to 15 mg daily (R15) if creatinine clearance is 30–49 mL/min.

SSE = Stroke and systemic embolization; CNS = Central nervous system; D150: Dabigatran 150 mg twice daily; D75: Dabigatran 75 mg twice daily; R20: Rivaroxaban 20 mg daily; R15: Rivaroxaban 15 mg daily; A5:
Apixaban 5 mg twice daily; A2.5: Apixaban 2.5 mg twice daily. *p values and CI adjusted for multivariable baseline differences using proportional hazards. The reduced group was the reference group. Some results were
not available (N/A) either because the univariable analysis was not significant or because there were too few patients in one or both outcome groups for a meaningful analysis.

0.9
9.5

0.005

N/A
N/A
1.091
(CI: 0.28 to 4.2)
0.083
(CI: 0.01 to 0.7)
N/A
N/A
0.18
%/year
0
0
3.7
%/year
0.8
0.8
8.3
%/year
0
0.5
1.6

SSE
CNS bleed
Non-CNS
bleed
All-cause
mortality

%/year
1.1
2.2
12.1

N/A
N/A
< 0.001

N/A
N/A
0.343
(CI: 0.07 to 1.62)
N/A

%/year
1.1
1.7
12.4

%/year
0
0.6
7.2

N/A
0.32
0.18

N/A
N/A
1.16
(CI: 0.53 to 2.5)
N/A

A5
(n =
68)
Univariable p value
(log rank test)
R20
(n =
74)
R15
(n =
224)
Multivariable
hazard ratio
(95 % CI) *
Univariable p value
(log rank test)
D150
(n =
57)
D75
(n =
53)
Events

Table 3
Time to event comparison of the reduced and full doses for each individual DOAC (Dabigatran, Rivaroxaban, and Apixaban).

Multivariable
hazard ratio
(95 % CI) *

A2.5
(n =
236)

Univariable p value
(log rank test)

Multivariable
hazard ratio
(95 % CI) *

IJC Heart & Vasculature 43 (2022) 101130

3. Results
3.1. Baseline characteristics
Thirty-three baseline characteristics were collected (Table 1). The
first analysis combined all the DOACs in a multivariable comparison of
patients prescribed either a reduced or full dose DOAC. The following
variables were identified as being significantly different: compared to
the full dose group, patients prescribed the reduced dose were older (p
< 0.001), had lower creatinine clearance (p = 0.001), were more often
on antiplatelet therapy (ASA p = 0.004, ASA + clopidogrel p < 0.001),
and had a higher prevalence of new-onset AF (p = 0.001). In contrast,
full dose DOAC patients were more likely to have chronic AF (p =
0.011).
A second analysis of the baseline characteristics of patients pre
scribed either the reduced or full dose of the individual DOACs was
conducted. Edoxaban was prescribed to only one patient, hence no
further analysis of the edoxaban group was performed. When D75 was
compared to D150 (Table 1), patients prescribed the reduced dose were
older (p < 0.001), more often had new-onset AF (p = 0.033) and had
worse renal function (p = 0.037). The number of patients prescribed
their respective dabigatran dose on label was 28.3 % for the reduced
dose and 100 % for the full dose, showing a significant univariable
difference (p < 0.001). However, multivariable testing to assess the
difference could not be done because all the patients in the full dose
group were prescribed the dose on label. Compliance with the guidelines
was determined in all but 2 patients in the D150 group.
When patients were prescribed either R15 or R20 daily, the differ
ences were similar to those found for dabigatran (Table 1). Notably,
those receiving R15 were older (p < 0.001), more often had new-onset
AF (p < 0.001) and had a worse renal function with higher serum
creatinine (p < 0.001). In addition, patients in the R15 group were more
often men (p < 0.001), more often treated with aspirin (p = 0.006),
more likely to have a pacemaker (p = 0.011), and less likely to be pre
scribed the reduced dose as per label (p = 0.03).
When patients were prescribed either A2.5 or A5, those receiving
A2.5 had a lower body mass index (p = 0.004), more commonly were
prescribed aspirin and clopidogrel (p = 0.044), had lower creatinine
clearance (p < 0.001), were more likely to have heart failure (p = 0.004)
and were less likely to be prescribed the reduced dose as per label (p <
0.001) (Table 1). As expected, based on the dosing guidelines the
reduced dose DOAC groups had worse kidney function.

4
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Fig. 2. Kaplan-Meier curves for time to SSE (A), death (B), non-CNS bleed (C), and CNS bleed (D) for all reduced dose and full dose DOAC groups.
Table 4
Event rates from post hoc age-related analyses of the RE-LY, ROCKET-AF, and ARISTOTLE trials.
Events

Dabigatran (rE-LY)

Rivaroxaban (ROCKET-AF)

Apixaban (ARISTOTLE)

Age (years)

80–84 (n = 2305)

≥85 (n = 722)
D150
2.15

≥75 years
(n = 3111)
R15 or R20*
2.29

≥75 years
(n = 5678)
A2.5
1.65

Dose
SSE
(%/yr)
Major bleeding
(%/yr)
Intracranial bleeding (%/yr)
All-cause mortality
(%/yr)

D110
1.95

D150
1.73

D110
1.61

A5
1.54

5.01

5.91

6.00

7.29

4.86

3.29

3.21

0.35
6.05

0.64
6.42

0.23
11.07

1.07
9.23

0.66
Not reported

0.43
5.42

D110: Dabigatran 110 mg twice daily; D150: Dabigatran 150 mg twice daily; R15: Rivaroxaban 15 mg daily, R20: Rivaroxaban 20 mg daily; A2.5: Apixaban 2.5 mg
twice daily, A5: Apixaban 5 mg twice daily.
*
Analysis did not differentiate between R15 and R20.

3.2. Outcomes

%/yr.) compared to the full dose DOAC group (1.75 %/yr.), (p < 0.001
univariable). This difference remained significant after correcting for
baseline differences (p = 0.013 multivariable) (Table 2). The compari
son of the clinical outcomes for the reduced and full dose of individual
DOACs mirrored the comparison of the combined DOAC groups
(Table 3).

At the end of the observation period, 245 (48 %) patients remained
on the reduced dose DOAC, and 118 (59 %) patients remained on the full
dose DOAC without an outcome event (Fig. 1). Outcomes were reported
as time-to-first - event (Tables 2 and 3, Figs. 1 and 2). The rate of SSE for
the reduced dose group was 1.02 %/yr, and for the full dose group 0
%/yr. (Fig. 1, Table 2). The rate of CNS bleeds was similarly low in both
groups and was 1.45 %/yr. for the reduced group and 0.44 %/yr for the
full dose group (p = 0.11 univariable). The rate of non-CNS bleeds was
10.89 and 4.15 %/yr (p < 0.001 univariable) for the reduced dose and
full dose groups, respectively. When the rates of non-CNS bleeds were
corrected for differences in baseline characteristics using a multivariable
analysis, the significant difference between the reduced and the full dose
DOAC groups (Table 2) was no longer present (p = 0.249). For all-cause
mortality, the rate was higher in the reduced dose DOAC group (6.26

4. Discussion:
This retrospective analysis of a multi-specialty practice database
from a single center was designed to fill a knowledge gap by comparing
patients ≥ 80 years old with atrial fibrillation prescribed either a
reduced or full dose DOAC. While DOAC use in octogenarians with AF
has been reported in both randomized and observational studies, these
previously published analyses have focused on comparisons between
DOACs and warfarin [9–12,19–23].
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With respect to baseline characteristics, this study reports that pa
tients prescribed a reduced DOAC were older, had worse renal function,
and were more often prescribed anti-platelet agents. With regards to
outcomes, the rates of SSE and CNS bleeds were low independent of the
individual DOAC prescribed, the DOAC dose, and the baseline risk. This
finding is consistent with reported results from the pivotal clinical trials
that led to the approval of each DOAC [9–12] (Table 4). Non-CNS bleed
rates were higher in the reduced dose DOAC group. This difference was
no longer statistically different when correcting for baseline differences.
By contrast, mortality was found to be higher in the reduced dose DOAC
group and was independent of the baseline characteristics. A limitation
of the mortality analysis was that the cause of death in most patients
could not be accurately determined.
The impact of DOACs on outcomes has been studied extensively, but
data comparing reduced and full dose treatment is sparse, particularly in
patients ≥ 80 years. Thus, despite the limitation of this single-center
retrospective study, our analysis provides useful information that
could be used in further research involving larger patient groups.
This study also raises important questions regarding appropriate
dosing of DOACs in octogenarians with AF. A significant number of
patients in this analysis were inappropriately prescribed the reduced and
full dose DOAC according to the current FDA-approved dosing guide
lines. Only 52.1 % of the patients receiving the reduced dose DOAC and
83.1 % of those receiving the full dose DOAC were prescribed the doses
according to the guidelines. These findings are consistent with an
observational study from Naples, Italy which evaluated the appropri
ateness of DOAC dosing in AF patients ≥ 80 years [22]. They reported
that out of 178 patients, 19 patients (25.6 %) were overdosed, and 56
patients (74.4 %) were underdosed according to guidelines. They also
reported that survival was significantly reduced in underdosed patients
compared to those who received the guideline-directed DOAC dose (p <
0.001).
Renal function is a critical variable concerning the safety of all
DOACs [24–27] and requires continuous monitoring for dose adjust
ment [27]. In our report, patients who were prescribed the reduced dose
DOAC had worse renal function compared to those prescribed the full
dose, with a CrCl of 44.1 ± 16.0 for the reduced group and 59.4 ± 14.1
for the full dose group (p < 0.001). The pivotal DOAC clinical trials did
not include patients with a CrCl < 30 (rE-LY, ROCKET-AF, and ENGAGEAF) [9–10,12] or with a CrCl < 25 in the ARISTOTLE trial [11]. Current
guidelines recommend the use of DOACs in CKD stages I-IV. The
exception is dabigatran which is not used in CKD stage IV [28]. The use
of oral anticoagulants in CKD stage IV remains at the discretion of the
prescribing clinician [29]. Apixaban is approved for use in patients with
ESRD based on observational studies [30]. In addition, current guide
lines do not require dose reduction for renal dysfunction alone, which
includes patients on dialysis [31].
Between 17 and 46.5 % of patients with atrial fibrillation have cor
onary artery disease [32–34]. The management of these patients is
challenging because of the perceived need for concomitant use of anti
platelet therapy, which increases the risk of bleeding [35–36]. In this
analysis, the concomitant use of antiplatelet agents was one factor
associated with increased non-CNS bleeding.

Thus topics requiring further research should focus on outcomes related
to compliance with guideline -directed dosing and evaluating the inci
dence and etiology of non-CNS bleeds and the cause of death in octo
genarians with AF.
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